{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:05:58Z","timestamp":1774951558564,"version":"3.50.1"},"reference-count":32,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Accurate assessment of liver fibrosis is essential for treatment decisions in patients with chronic hepatitis B (CHB). Although liver biopsy is considered the reference standard, its invasive nature limits routine use. Serum-based non-invasive fibrosis scores have been proposed as alternatives; however, their diagnostic performance in CHB remains variable. This study aimed to compare multiple serum-based non-invasive fibrosis scores with liver biopsy findings and to evaluate their association with histological activity. Materials and Methods: This retrospective cross-sectional study included 219 adult patients with CHB who underwent liver biopsy with simultaneous laboratory evaluation. Patients with viral co-infections (HIV, HCV, or HDV), metabolic syndrome, diabetes mellitus, hepatic steatosis, or incomplete data were excluded. Non-invasive fibrosis scores\u2014including APRI, FIB-4, AST\/ALT ratio (AAR), age\u2013platelet index (API), GGT-to-platelet ratio (GPR), Lok index, modified Forns index, Albumin\u2013Bilirubin (ALBI) score, and red cell distribution width (RDW)-based indices\u2014were calculated using routine laboratory parameters. Histopathological fibrosis staging served as the reference standard. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis, and areas under the curve (AUC) were compared using the DeLong test. Associations with histological activity index (HAI) were assessed using Spearman correlation. Results: For the prediction of significant fibrosis (\u2265F2), FIB-4 demonstrated the highest AUC, followed by ALBI and APRI. For advanced fibrosis (\u2265F3), FIB-4 again showed the highest AUC, followed by APRI and GPR. For significant fibrosis (\u2265F2), DeLong analysis revealed no statistically significant differences between FIB-4 and the other serum-based scores (p &gt; 0.05). APRI (r = 0.556, p &lt; 0.001) and FIB-4 (r = 0.463, p &lt; 0.001) showed the strongest correlations with HAI. In ROC analysis for moderate-to-severe histological activity (HAI \u2265 4), APRI demonstrated the highest diagnostic accuracy (AUC = 0.677). Conclusions: Serum-based non-invasive fibrosis scores demonstrate comparable but overall modest diagnostic performance for biopsy-confirmed fibrosis in patients with chronic hepatitis B. Indices such as FIB-4 and APRI demonstrated relatively better discrimination and may be considered as screening or rule-out tools in selected clinical contexts. APRI and FIB-4 also show associations with histological activity; however, their clinical application should be interpreted with caution, given their moderate discriminatory capacity.<\/jats:p>","DOI":"10.3390\/medicina62040646","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:40:52Z","timestamp":1774878052000},"page":"646","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Performance of Serum-Based Non-Invasive Fibrosis Scores Compared with Liver Biopsy in Patients with Chronic Hepatitis B"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-9109","authenticated-orcid":false,"given":"Umut Devrim","family":"Binay","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-7187","authenticated-orcid":false,"given":"Faruk","family":"Karake\u00e7ili","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-7740","authenticated-orcid":false,"given":"Or\u00e7un","family":"Barkay","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1394-993X","authenticated-orcid":false,"given":"Bet\u00fcl","family":"Kuru","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Erzincan Binali Y\u0131ld\u0131r\u0131m University, 24100 Erzincan, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD\/IDSA practice guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2025","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lin, C.-L., and Kao, J.-H. (2021). Novel biomarkers for the management of chronic hepatitis B virus infection. Hepatitis B Virus and Liver Disease, Springer.","DOI":"10.1007\/978-981-16-3615-8_10"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bera, C., Hamdan-Perez, N., and Patel, K. (2024). Non-invasive assessment of liver fibrosis in hepatitis B patients. J. Clin. Med., 13.","DOI":"10.3390\/jcm13041046"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.aohep.2021.100544","article-title":"A novel non-invasive score for the prediction of advanced fibrosis in patients with chronic hepatitis B","volume":"27","author":"Okdemir","year":"2022","journal-title":"Ann. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.36519\/idcm.2023.276","article-title":"How successful are APRI and FIB-4 scores in predicting liver fibrosis in chronic hepatitis B patients?","volume":"5","year":"2023","journal-title":"Infect. Dis. Clin. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e20548","DOI":"10.1097\/MD.0000000000020548","article-title":"Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis in chronic hepatitis B virus\u2013infected patients with high HBV DNA and normal or mildly elevated ALT levels","volume":"99","author":"Wang","year":"2020","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.51821\/85.1.9156","article-title":"GPR, King\u2019s score and S-index are superior to other non-invasive fibrosis markers in predicting liver fibrosis in chronic hepatitis B patients","volume":"85","author":"Ekin","year":"2022","journal-title":"Acta Gastro.-Enterol. Belg."},{"key":"ref_11","first-page":"419","article-title":"Evaluation of the diagnostic validity of noninvasive tests for predicting liver fibrosis stage in chronic hepatitis B patients","volume":"83","author":"Tatar","year":"2020","journal-title":"Acta Gastro.-Enterol. Belg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s42399-025-02005-z","article-title":"Evaluating non-invasive biomarkers and composite scores for liver fibrosis diagnosis in hepatitis B and C infections","volume":"7","author":"Addissouky","year":"2025","journal-title":"SN Compr. Clin. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-022-35729-w","article-title":"Systematic review and individual-patient-data meta-analysis of non-invasive fibrosis markers for chronic hepatitis B in Africa","volume":"14","author":"Johannessen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Xu, X.-Y., Kong, H., Song, R.-X., Zhai, Y.-H., Wu, X.-F., Ai, W.-S., and Liu, H.-B. (2014). The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: A systematic review and meta-analysis of diagnostic test accuracy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100182"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.13446","article-title":"Systematic review with meta-analysis: Direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B","volume":"43","author":"Houot","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(24)00437-0","article-title":"Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: A systematic review and meta-analysis","volume":"10","author":"Liguori","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Borcak, D., Yesilbag, Z., Ozdemir, Y.E., Demir, A.S., Dogdas, E.S., Sezen, A.I., Unlu, E.C., Senoglu, S., Karaosmanoglu, H.K., and Yasar, K.K. (2025). Assessing liver fibrosis in chronic hepatitis B: Liver biopsy or non-invasive fibrosis markers?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14228164"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tamaki, N., Takaura, K., Higuchi, M., Yasui, Y., Itakura, J., Tsuchiya, K., Nakanishi, H., Izumi, N., and Kurosaki, M. (2024). Enhanced liver fibrosis score for diagnosing liver fibrosis in chronic hepatitis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14131317"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ozguler, M., Durak, S., Solmaz, O.A., Eser Karlidag, G., Gundag, O., Kirik, Y., Tanir, B., and Kara, S.S. (2025). The use of serum scoring systems in predicting liver fibrosis caused by chronic hepatitis B: A retrospective case-control study. Medicina, 61.","DOI":"10.3390\/medicina61081490"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1515\/mr-2024-0022","article-title":"A critical review of diagnostic and prognostic markers of chronic hepatitis B infection","volume":"4","author":"Hudu","year":"2024","journal-title":"Med. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cld.481","article-title":"Histologic and noninvasive estimates of liver fibrosis","volume":"6","author":"Bedossa","year":"2015","journal-title":"Clin. Liver Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.dld.2017.12.028","article-title":"A novel noninvasive index for the prediction of moderate to severe fibrosis in chronic hepatitis B patients","volume":"50","author":"Li","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1177\/0300060516664638","article-title":"Gamma-glutamyl transpeptidase to platelet ratio index is a good noninvasive biomarker for predicting liver fibrosis in Chinese chronic hepatitis B patients","volume":"44","author":"Wang","year":"2016","journal-title":"J. Int. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1111\/liv.13756","article-title":"Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B","volume":"38","author":"Wu","year":"2018","journal-title":"Liver Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/MEG.0000000000001973","article-title":"Development and evaluation of a novel noninvasive index for predicting significant fibrosis, advanced fibrosis, and cirrhosis in patients with chronic hepatitis B infection","volume":"33","author":"Kayadibi","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1056\/NEJMra2403308","article-title":"Noninvasive assessment of liver fibrosis","volume":"393","author":"Castera","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/jgh.14008","article-title":"Long-term liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy: Results from a 5-year cohort study","volume":"33","author":"Facciorusso","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3892\/etm.2020.8798","article-title":"Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B","volume":"20","author":"Tsuji","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.2147\/IDR.S427047","article-title":"RDW-SD is superior to RDW-CV in reflecting liver fibrosis stage in patients with chronic hepatitis B","volume":"16","author":"Yang","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_31","first-page":"579","article-title":"RDW predicts fibrosis in patients with chronic hepatitis B having persistently normal ALT levels","volume":"33","author":"Guller","year":"2023","journal-title":"Ethiop. J. Health Sci."},{"key":"ref_32","first-page":"e951084","article-title":"The silent face of chronic hepatitis B: Biopsy-supported fibrosis detection and the reliability of non-invasive scores (FIB-4, APRI) in inactive, gray zone, and immune-tolerant cases","volume":"31","year":"2025","journal-title":"Med. Sci. Monit."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/646\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:15:52Z","timestamp":1774948552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040646"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040646","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}